Plasma levels of matrix metalloproteinases and their inhibitors in hypertension

Marchesi, Chiara; Dentali, Francesco; Nicolini, E.; Maresca, Andrea Maria; Tayebjee, Mazahir H.; Franz, Marcus; Guasti, Luigina; Venco, Achille; Schiffrin, Ernesto L.; Lip, Gregory Y.H.; Grandi, Anna Maria

doi:10.1097/hjh.0b013e32834d249a

Cited by 99 publications

(65 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well known that long-term hypertension induces cardiovascular extracellular matrix remodeling. 4,22 Mechanical stretch of the vasculature, as seen in hypertension, induces vascular extracellular remodeling by activation of metalloproteinase-2 and metalloproteinase-9, 23 which both are proteases that play an important role in the degradation of collagen XVIII to endostatin. Moreover, experimental studies show that damages to the vasculature, 24 the myocardium, 25 and the kidneys 26 lead to increased expression of endostatin in these tissues, and that circulating concentrations of endostatin are elevated in patients with prevalent cardiovascular diseases 20,[27][28][29][30] or chronic kidney disease.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, a possible explanation could be that increased endostatin mirrors a systemic elevated angiogenic activity, reflecting increased neovascularization induced by vascular, myocardial, or renal ischemia, similar as the role suggested for vascular endothelial growth factor. 4,13,14,[36][37][38] Endostatin has also been shown to exert acute reductions in blood pressure via a release of NO, 39 and individuals with Down Syndrome have significantly higher circulating levels of endostatin and exhibit lower blood pressure compared with control subjects. 40,41 This may indicate that endostatin, per se, may exert a blood pressure lowering effect.…”

Section: Discussionmentioning

confidence: 99%

“…3 An increased turnover of the extracellular matrix has been suggested as a key element in the underlying pathophysiology of this hypertensive target-organ damage. 4 However, till date, relevant endogenous biomarkers mirroring hypertensionrelated cardiovascular remodeling are scarce.…”

mentioning

confidence: 99%

“…4,13,14 Meanwhile, extracellular matrix proteinases also increase in those tissues. 4,15,16 Thus, endostatin, a cleaved product of collagen XVIII, could be an indicator of adverse extracellular remodeling in hypertension.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Association Between Circulating Endostatin, Hypertension Duration, and Hypertensive Target-Organ Damage

et al. 2013

View full text Add to dashboard Cite

Abstract-Our aim is to study associations between circulating endostatin, hypertension duration, and hypertensive target-organ damage. Long-term hypertension induces cardiovascular and renal remodeling. Circulating endostatin, a biologically active derivate of collagen XVIII, has been suggested to be a relevant marker for extracellular matrix turnover and remodeling in various diseases. However, the role of endostatin in hypertension and hypertensive targetorgan damage is unclear. Serum endostatin was measured in 2 independent community-based cohorts: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; women 51%; n=812; mean age, 75 years) and the Uppsala Longitudinal Study of Adult Men (ULSAM; n=785; mean age, 77.6 years). Retrospective data on blood pressure measurements and antihypertensive medication (PIVUS >5 years, ULSAM >27 years), and cross-sectional data on echocardiographic left ventricular mass, endothelial function (endothelium-dependent vasodilation assessed by the invasive forearm model), and urinary albumin/creatinine ratio were available. In PIVUS, participants with ≥5 years of history of hypertension portrayed 0.42 SD (95% confidence interval, 0.23-0.61; P<0.001) higher serum endostatin, compared with that of normotensives. This association was replicated in ULSAM, in which participants with 27 years hypertension duration had the highest endostatin (0.57 SD higher; 95% confidence interval, 0.35-0.80; P<0.001).In addition, higher endostatin was associated with higher left ventricular mass, worsened endothelial function, and higher urinary albumin/creatinine ratio (P<0.03 for all) in participants with prevalent hypertension. Circulating endostatin is associated with the duration of hypertension, and vascular, myocardial, and renal indices of hypertensive target-organ damage.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Association Between Circulating Endostatin, Hypertension Duration, and Hypertensive Target-Organ Damage

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Therefore, gelatinases play an important role in vascular remodeling. In human and animal studies, it was demonstrated that increased matrix metalloproteinase-2 and matrix metalloproteinase-9 activity are related with the destruction of the elastic lamina of arteries and the aneurysm formation (9)(10)(11). In patients with hypertrophic cardiomyopathy, it have been suggested that modifications of matrix metalloproteinase-2 and tissue inhibitors of matrix metalloproteinase-2 release and activity can be related or responsible for cardiac remodeling mechanisms (12).…”

Section: Introductionmentioning

confidence: 99%

Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases levels in pediatric patients with congenital heart disease: Relationship to cardiac functions

Kılıç

Uçar²,

Özdemir³

et al. 2014

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Objective: The pathological effects of matrix metalloproteinases and their tissue inhibitors in cardiovascular diseases are of considerable interest. In our study, we aimed to determine and evaluate the potential significance of circulating matrix metalloproteinases-2 and 9, tissue inhibitors of matrix metalloproteinases-1 and 2 levels in four patient subgroup of pediatric cardiology field and expose pathophysiologic differences between these groups. Methods: Eighty-seven patients with the diagnosis of congenital heart disease and 47 healthy controls were enrolled in the study. The study group was stratified to 4 subgroups; 14 patients with right ventricular volume overload, 30 patients with left ventricular volume overload, 19 patients with left to right shunt who developed pulmonary hypertension and 24 patients with cyanotic congenital heart disease. For evaluation of the relationships between serum matrix metalloproteinases and their tissue inhibitors levels with cardiac structures and functions; complete blood count, arterial oxygen saturation, detailed echocardiographic measurements (including tissue Doppler) in all patients and hemodynamic parameters of the patients who went to cardiac catheterization were recorded. Serum matrix metalloproteinase levels were determined by ELISA test. Statistical evaluations were performed with SPSS 16.0. For parameters showing normal distribution, comparisons were made with t-test and ANOVA test. However, for parameters without normal distribution, groups were compared with Mann-Whitney U test and KruskalWallis test. Results: We demonstrated that serum tissue inhibitors of matrix metalloproteinases-1 levels of patients with pulmonary hypertension secondary to congenital heart diseases were significantly higher than the patients with left to right shunt without pulmonary hypertension and controls (p<0.01). Although serum matrix metalloproteinases and their tissue inhibitors levels in patients with cyanotic congenital heart diseases and patients with right or left ventricular volume overload were found to be altered when compared with controls but not significant. Conclusion: Our data may suggest the possible role of matrix metalloproteinases and their tissue inhibitors on myocardial remodeling in congenital heart defects and especially in patients who developed pulmonary hypertension. (Anadolu Kardiyol Derg 2014; 14: 531-41)

show abstract

Reappraisal of Quantitative Gel Zymography for Matrix Metalloproteinases

Prescimone

Tognotti

Caselli

et al. 2014

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

show abstract

Plasma levels of matrix metalloproteinases and their inhibitors in hypertension

Abstract: These results suggest that MMP-2, MMP-9 and TIMP-1 may have a role as biomarkers of cardiovascular remodeling in hypertension. If these results are confirmed in prospective clinical studies, they could provide new tools to stratify cardiovascular risk in hypertensive patients.

Cited by 99 publications

References 56 publications

Association Between Circulating Endostatin, Hypertension Duration, and Hypertensive Target-Organ Damage

Association Between Circulating Endostatin, Hypertension Duration, and Hypertensive Target-Organ Damage

Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases levels in pediatric patients with congenital heart disease: Relationship to cardiac functions

Reappraisal of Quantitative Gel Zymography for Matrix Metalloproteinases

Contact Info

Product

Resources

About